What's breaking now, across thousands of outlets.
We haven't written up this one. Federal Reserve Board has the full story — the link below goes straight to it.
First-time homebuyers are not only historically old but also increasingly reliant on family wealth.
Plus news about Rezera, ANI Pharmaceuticals, Cloudbreak Pharma and Anaheim Bio. RevMed’s stock jumps on early Rasonque sales: The RAS drug developer reported sales of its pancreatic cancer therapy…
Sequential revenue jumped 77% while cash losses shrank sharply.
Josh Brown points out this stock has made a monster move out of a long consolidation.
Josh Brown points out this stock has made a monster move out of a long consolidation.
AMD's expanding AI ambitions could create significant opportunities, but investors still need proof that new technology will generate meaningful returns.